KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Long-Term Debt Repayments (2018 - 2025)

Bionano Genomics' Long-Term Debt Repayments history spans 5 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Long-Term Debt Repayments rose 20.5% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $6.9 million, up 129.17%, while the annual FY2024 figure was $5.0 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q3 2025 was $1.9 million at Bionano Genomics, up from $1.5 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $17.0 million in Q2 2021 and bottomed at -$2.0 million in Q4 2021.
  • The 3-year median for Long-Term Debt Repayments is $1.5 million (2024), against an average of $3.1 million.
  • The largest annual shift saw Long-Term Debt Repayments surged 486.55% in 2021 before it grew 3.88% in 2025.
  • A 3-year view of Long-Term Debt Repayments shows it stood at -$2.0 million in 2021, then surged by 199.5% to $2.0 million in 2024, then fell by 6.25% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Long-Term Debt Repayments are $1.9 million (Q3 2025), $1.5 million (Q2 2025), and $1.5 million (Q1 2025).